- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT00086866
Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With Surgery
Randomized, Open Phase II Study of Immunization With the Recombinant MAGE-3 Protein Combined With Adjuvant AS02B or AS15 in Patients With Unresectable and Progressive Metastatic Cutaneous Melanoma
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells.
PURPOSE: This randomized phase II trial is studying two different regimens of vaccine therapy and comparing them to see how well they work in treating patients with stage III or stage IV melanoma that cannot be removed with surgery.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
OBJECTIVES:
Primary
- Compare the objective response rate (complete and partial response) in patients with unresectable stage III or stage IV M1a cutaneous melanoma immunized with vaccine comprising D1/3-MAGE-3-His fusion protein and SB-AS02B adjuvant vs SB-AS15 adjuvant.
- Compare the activity of SB-AS02B adjuvant vs SB-AS15 adjuvant, in terms of maximizing the antigenicity of MAGE-3, in patients treated with these regimens.
- Compare the rate of grade 3/4 vaccine-related toxicity in patients treated with these regimens.
Secondary
- Compare progression-free survival in patients treated with these regimens.
OUTLINE: This is a randomized, open label, parallell-group, multicenter study. Patients are stratified according to disease stage (III in transit vs other stage III vs IV), presence of lesion ≥ 20 mm (yes vs no), and participating center. Patients are randomized to 1 of 2 treatment arms.
Induction therapy
- Arm I: Patients receive immunization comprising D1/3-MAGE-3-His fusion protein and SB-AS02B adjuvant intramuscularly (IM) once weekly on weeks 1, 3, 5, 7, 9, and 11.
- Arm II: Patients receive immunization comprising D1/3-MAGE-3-His fusion protein SB-AS15 adjuvant IM once weekly on weeks 1, 3, 5, 7, 9, and 11.
Patients achieving a clinical complete response (CR), partial response (PR), stable disease (SD), or slow progressive disease (SPD) proceed to maintenance therapy.
- Maintenance therapy: Patients in both arms receive immunization (according to their randomized arm) once weekly on weeks 15, 18, 21, 24, 27, 30, 34, 40, 46, and 52.
Patients maintaining a CR, PR, or SD proceed to long-term treatment.
- Long-term treatment: Beginning 3 months after completion of maintenance therapy, patients in both arms receive immunization (according to their randomized arm) once every 3 months for 4 courses and then once every 6 months for 4 courses.
Treatment continues in both arms in the absence of disease progression that does not correspond to SPD status, unacceptable toxicity, or the diagnosis of an autoimmune disease.
Patients are followed every 12 weeks.
PROJECTED ACCRUAL: A total of 68 patients (34 patients per treatment arm) will be accrued for this study.
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 2
Contacten en locaties
Studie Locaties
-
-
-
Brussels, België, 1000
- Institut Jules Bordet
-
Brussels, België, 1070
- Hopital Universitaire Erasme
-
-
-
-
-
Berlin, Duitsland, D-12200
- Charite - Universitaetsmedizin Berlin - Campus Benjamin Franklin
-
Mannheim, Duitsland, D-68135
- Klinikum der Stadt Mannheim
-
Wuerzburg, Duitsland, D-97080
- Universitaets - Kinderklinik Wuerzburg
-
-
-
-
-
Hyeres, Frankrijk, 83400
- Clinique Sainte-Marguerite
-
Lille, Frankrijk, 59037
- Centre Hospitalier Regional et Universitaire de Lille
-
Montpellier, Frankrijk, 34295
- Hopital St. Eloi
-
Nantes, Frankrijk, 44093
- CHR Hotel Dieu
-
Paris, Frankrijk, 75248
- Institut Curie Hopital
-
Villejuif, Frankrijk, F-94805
- Institut Gustave Roussy
-
-
-
-
-
Aviano, Italië, 33081
- Centro di Riferimento Oncologico - Aviano
-
Naples, Italië, 80131
- Istituto Nazionale per lo Studio e la Cura dei Tumori
-
Padova, Italië, 35128
- Azienda Ospedaliera di Padova
-
Siena, Italië, 53100
- Università di Siena
-
-
-
-
-
Leiden, Nederland, 2300 RC
- Leiden University Medical Center
-
Rotterdam, Nederland, 3008 AE
- Daniel Den Hoed Cancer Center at Erasmus Medical Center
-
-
-
-
-
Barcelona, Spanje, 08036
- Hospital Clinic de Barcelona
-
Madrid, Spanje, 28041
- Hospital Universitario 12 de Octubre
-
-
-
-
England
-
London, England, Verenigd Koninkrijk, EC1A 7BE
- Saint Bartholomew's Hospital
-
Manchester, England, Verenigd Koninkrijk, M20 4BX
- Christie Hospital Nhs Trust
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
DISEASE CHARACTERISTICS:
Histologically confirmed cutaneous melanoma
- Unresectable stage III OR stage IV M1a disease
- Documented progressive disease within the past 12 weeks
- Measurable disease
- Skin, soft tissue, or lymph node metastasis allowed provided the disease is not amenable to curative treatment with surgery
- Tumor must express the MAGE-3 gene by reverse transcription polymerase chain reaction analysis (more than 1% of the positive MAGE-3 control included in the assay)
- No visceral metastases within the past 56 days by imaging
PATIENT CHARACTERISTICS:
Age
- 18 and over
Performance status
- ECOG 0-1
Life expectancy
- Not specified
Hematopoietic
- Hemoglobin ≥ lower limit of normal (LLN)
- WBC ≥ LLN
- Lymphocyte count ≥ LLN
- Platelet count ≥ LLN
- No bleeding disorders
Hepatic
- Bilirubin ≤ upper limit of normal (ULN)
- Lactic dehydrogenase ≤ ULN
- AST and ALT ≤ 2 times ULN
- PT and aPTT normal
- Hepatitis B surface antigen negative (antibody test may be positive)
- Hepatitis C antibody negative
Renal
- Creatinine ≤ ULN
Cardiovascular
- No clinically significant heart disease (CTC grade III or IV)
Immunologic
- No autoimmune disease (vitiligo allowed)
- No anti-nuclear antibody titer ≥ 1/320 OR equal to 1/160 AND auto-antibodies directed against specific auto-antigens
- No immunodeficiency
- No active infection requiring antibiotic therapy
- HIV negative
Other
- Not pregnant
- Negative pregnancy test
- Fertile patients must use effective contraception during and for 3 months after study participation
- No other malignancy within the past 5 years except surgically cured basal cell or squamous cell skin cancer or carcinoma in situ of the cervix
- No other serious acute or chronic illness requiring concurrent medications
- No psychological, familial, sociological, or geographical condition that would preclude study compliance
PRIOR CONCURRENT THERAPY:
Biologic therapy
- More than 8 weeks since prior adjuvant vaccine therapy
- No prior vaccine therapy containing a MAGE-3 antigen
- No prior vaccine therapy for metastatic melanoma
- No concurrent immunomodulating agents (e.g., BCG)
Chemotherapy
- No prior systemic chemotherapy
- No concurrent chemotherapy
Endocrine therapy
No concurrent corticosteroids
- Concurrent prednisone or equivalent allowed provided the dose is ≤ 40 mg/day and treatment duration is for no more than 3 weeks
- Concurrent inhaled and topical steroids are allowed
Radiotherapy
- No prior radiotherapy to the spleen
No concurrent radiotherapy to > 20% of all existing lesions (i.e., target lesions, non-target lesions, and nonmeasurable lesions)
- Concurrent local low-dose (≤ 20 Grays) radiotherapy allowed
Surgery
- Recovered from prior surgery or biopsy
- No prior organ allograft
- No prior splenectomy
- Concurrent surgery to a limited number of lesions allowed for patients with a complete response, partial response, or stable disease after at least 3 courses of study therapy
Other
- No prior systemic anticancer therapy
- More than 4 weeks since prior isolated limb perfusion therapy
- No other concurrent anticancer therapy
- No other concurrent immunosuppressive agents
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Masker: Geen (open label)
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
|---|
|
Response rate (complete response and partial response) as assessed by RECIST criteria
|
|
Vaccine-related toxicity as assessed by CTCAE v3
|
Secundaire uitkomstmaten
Uitkomstmaat |
|---|
|
Progressievrije overleving
|
|
Rate of stabilization as assessed by RECIST criteria
|
|
Rate of mixed response as assessed by RECIST criteria
|
|
Rate of immune response
|
Medewerkers en onderzoekers
Onderzoekers
- Studie stoel: Willem H. J. Kruit, MD, PhD, Daniel Den Hoed Cancer Center at Erasmus Medical Center
Publicaties en nuttige links
Algemene publicaties
- Ulloa-Montoya F, Louahed J, Dizier B, Gruselle O, Spiessens B, Lehmann FF, Suciu S, Kruit WH, Eggermont AM, Vansteenkiste J, Brichard VG. Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy. J Clin Oncol. 2013 Jul 1;31(19):2388-95. doi: 10.1200/JCO.2012.44.3762. Epub 2013 May 28.
- Kruit WH, Suciu S, Dreno B, et al.: Immunization with recombinant MAGE-A3 protein combined with adjuvant systems AS15 or AS02B in patients with unresectable and progressive metastatic cutaneous melanoma: A randomized open-label phase II study of the EORTC Melanoma Group (16032- 18031). [Abstract] J Clin Oncol 26 (Suppl 15): A-9065, 2008.
- Louahed J, Gruselle O, Gaulis S, et al.: Expression of defined genes identified by pretreatment tumor profiling: association with clinical responses to the GSK MAGE- A3 immunotherapeutic in metastatic melanoma patients (EORTC 16032-18031). [Abstract] J Clin Oncol 26 (Suppl 15): A-9045, 2008.
- Kruit WH, Suciu S, Dreno B, Mortier L, Robert C, Chiarion-Sileni V, Maio M, Testori A, Dorval T, Grob JJ, Becker JC, Spatz A, Eggermont AM, Louahed J, Lehmann FF, Brichard VG, Keilholz U. Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma. J Clin Oncol. 2013 Jul 1;31(19):2413-20. doi: 10.1200/JCO.2012.43.7111. Epub 2013 May 28.
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- EORTC-16032-18031
- EORTC-18031
- EORTC-16032
- GSK-249553/008
- 2004-001937-40 (EudraCT-nummer)
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .